| Gene Name |
Gene ID |
KEGG ID |
Pathway Name |
EC No. |
| BRAF | 673 | hsa04010 | MAPK signaling pathway | 2.7.11.1 |
| BRAF | 673 | hsa04012 | ErbB signaling pathway | 2.7.11.1 |
| BRAF | 673 | hsa04062 | Chemokine signaling pathway | 2.7.11.1 |
| BRAF | 673 | hsa04150 | mTOR signaling pathway | 2.7.11.1 |
| BRAF | 673 | hsa04270 | Vascular smooth muscle contraction | 2.7.11.1 |
| BRAF | 673 | hsa04510 | Focal adhesion | 2.7.11.1 |
| BRAF | 673 | hsa04650 | Natural killer cell mediated cytotoxicity | 2.7.11.1 |
| BRAF | 673 | hsa04720 | Long-term potentiation | 2.7.11.1 |
| BRAF | 673 | hsa04722 | Neurotrophin signaling pathway | 2.7.11.1 |
| BRAF | 673 | hsa04730 | Long-term depression | 2.7.11.1 |
| BRAF | 673 | hsa04810 | Regulation of actin cytoskeleton | 2.7.11.1 |
| BRAF | 673 | hsa04910 | Insulin signaling pathway | 2.7.11.1 |
| BRAF | 673 | hsa04914 | Progesterone-mediated oocyte maturation | 2.7.11.1 |
| BRAF | 673 | hsa05160 | Hepatitis C | 2.7.11.1 |
| BRAF | 673 | hsa05200 | Pathways in cancer | 2.7.11.1 |
| BRAF | 673 | hsa05210 | Colorectal cancer | 2.7.11.1 |
| BRAF | 673 | hsa05211 | Renal cell carcinoma | 2.7.11.1 |
| BRAF | 673 | hsa05212 | Pancreatic cancer | 2.7.11.1 |
| BRAF | 673 | hsa05213 | Endometrial cancer | 2.7.11.1 |
| BRAF | 673 | hsa05214 | Glioma | 2.7.11.1 |
| BRAF | 673 | hsa05215 | Prostate cancer | 2.7.11.1 |
| BRAF | 673 | hsa05216 | Thyroid cancer | 2.7.11.1 |
| BRAF | 673 | hsa05218 | Melanoma | 2.7.11.1 |
| BRAF | 673 | hsa05219 | Bladder cancer | 2.7.11.1 |
| BRAF | 673 | hsa05220 | Chronic myeloid leukemia | 2.7.11.1 |
| BRAF | 673 | hsa05221 | Acute myeloid leukemia | 2.7.11.1 |
| BRAF | 673 | hsa05223 | Non-small cell lung cancer | 2.7.11.1 |
| BRAF | 673 | hsa04010 | MAPK signaling pathway | 2.7.11.1 |
| BRAF | 673 | hsa04012 | ErbB signaling pathway | 2.7.11.1 |
| BRAF | 673 | hsa04062 | Chemokine signaling pathway | 2.7.11.1 |
| BRAF | 673 | hsa04150 | mTOR signaling pathway | 2.7.11.1 |
| BRAF | 673 | hsa04270 | Vascular smooth muscle contraction | 2.7.11.1 |
| BRAF | 673 | hsa04510 | Focal adhesion | 2.7.11.1 |
| BRAF | 673 | hsa04650 | Natural killer cell mediated cytotoxicity | 2.7.11.1 |
| BRAF | 673 | hsa04720 | Long-term potentiation | 2.7.11.1 |
| BRAF | 673 | hsa04722 | Neurotrophin signaling pathway | 2.7.11.1 |
| BRAF | 673 | hsa04730 | Long-term depression | 2.7.11.1 |
| BRAF | 673 | hsa04810 | Regulation of actin cytoskeleton | 2.7.11.1 |
| BRAF | 673 | hsa04910 | Insulin signaling pathway | 2.7.11.1 |
| BRAF | 673 | hsa04914 | Progesterone-mediated oocyte maturation | 2.7.11.1 |
| BRAF | 673 | hsa05160 | Hepatitis C | 2.7.11.1 |
| BRAF | 673 | hsa05200 | Pathways in cancer | 2.7.11.1 |
| BRAF | 673 | hsa05210 | Colorectal cancer | 2.7.11.1 |
| BRAF | 673 | hsa05211 | Renal cell carcinoma | 2.7.11.1 |
| BRAF | 673 | hsa05212 | Pancreatic cancer | 2.7.11.1 |
| BRAF | 673 | hsa05213 | Endometrial cancer | 2.7.11.1 |
| BRAF | 673 | hsa05214 | Glioma | 2.7.11.1 |
| BRAF | 673 | hsa05215 | Prostate cancer | 2.7.11.1 |
| BRAF | 673 | hsa05216 | Thyroid cancer | 2.7.11.1 |
| BRAF | 673 | hsa05218 | Melanoma | 2.7.11.1 |
| BRAF | 673 | hsa05219 | Bladder cancer | 2.7.11.1 |
| BRAF | 673 | hsa05220 | Chronic myeloid leukemia | 2.7.11.1 |
| BRAF | 673 | hsa05221 | Acute myeloid leukemia | 2.7.11.1 |
| BRAF | 673 | hsa05223 | Non-small cell lung cancer | 2.7.11.1 |